Pfizer, Germany’s strike deal to develop cancer tumor treatment

Pfizer, Germany’s strike deal to develop cancer tumor treatment

Pfizer Inc. and Germany’s Merck KGaA are teaming up to develop a new tumor treatment product, in a move that will boost the U.S. company’s oncology business but reduce its full-year earnings per share.

Merck MRK, +0.11%  said Monday it will receive $850 million upfront to jointly develop and commercialize an anti-PD-L1 antibody with Pfizer PFE, -0.28%  and could receive a further $2 billion in regulatory and commercial milestone payments. Merck is already developing the drug as a treatment against various types of tumors.

“It is the largest deal in the pharmaceutical industry for a single asset in this stage of development,” said Belén Garijo, chief executive of Merck’s pharmaceutical division.

The deal also “enables Merck to accelerate its entry into the U.S. oncology market,” Garijo added.

The two companies will also push to advance Pfizer’s anti-PD-1 antibody — another tumor-fighting agent — into phase 1 trials, while Merck will co-promote Pfizer’s lung cancer drug XALKORI in the U.S. and other markets.

As a result of the transaction, Pfizer is downgrading its previous 2014 reported diluted earnings per share guidance to between $1.40 and $1.49, from between $1.50 and $1.59.

Both companies will jointly fund development and commercialization costs and will share all revenues from selling any anti-PD-L1 or anti-PD-1 products, Merck said.

Merck added that about 20 immuno-oncology clinical development programs are set to begin next year.

Growth in Merck’s pharmaceutical division, Merck Serono, was held back in the third quarter, reported Nov. 13, because of a 69% decline in royalty, license and commission income connected with patent expirations for arthritis drugs Humira and Enbrel. Third-quarter pharmaceutical sales were driven largely by growth in emerging markets such as China and Brazil.

The company has moved over the past year to bolster its non-pharmaceutical divisions through the acquisitions of the U.K.’s AZ Electronics PLC and U.S.-based Sigma-Aldrich Corp., a supplier of laboratory testing materials.

Merck KGaA isn’t affiliated with Merck & Co. of the U.S.

You’re invited: A free evening event focusing on investing opportunities in Europe

Will you be in London on Dec. 3? Then you’re invited to our MarketWatch Investing Insights event, “The worse Europe gets, the more you should invest.”

Governments are in trouble, reform efforts have stalled, unemployment is climbing. the news from the eurozone is bleak. And investors are fleeing. But that’s a mistake: The worse the economic data from Europe get, the more you should be buying. Why? Because actions by the ECB will boost asset prices and the stock market in particular. And, big exporters can grow sales. Lower costs and steady sales translate into higher profits and dividends. Join us for an evening of cocktails and conversation to explore these opportunities.

Our panel will be led by MarketWatch Columnist Matthew Lynn, a renowned financial journalist based in London and the author of “Bust: Greece, the euro and the Sovereign Debt Crisis.” He’ll be joined by Mark Hulbert, MarketWatch columnist and editor of the Hulbert Financial Digest.